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Abstract
Patients with ACO have significant poorer health-related quality of life and more severe functional limitations compared to 
asthma and COPD alone. Most commonly, chronic respiratory disease is associated with cardiovascular disease, such as arterial hyper-
tension. However, the impact of concomitant cardiac diseases on the quality of life and functional status of patients with ACO remains 
poorly understood.
The aim of the work was to study dynamics of functional condition and quality of life in with ACO and concomitant AH against 
the background of complex therapy.
Materials and methods. We selected for participating in the study 100 patients with ACO and concomitant AH. Examination 
of the patients included: clinical methods, spirometry, and questinaries – mMRS, CAT, SGRQ, performing 6MWT.
Results. After 16 weeks of treatment there were no changes in lung functional status in patients on standard treatment, at the 
same time, in group of patients who had an active rehabilitation program, there was a significant improvement in the bronchial response 
to the action of bronchodilators, although other indicators of the functional status of the lungs didn’t show significant changes. Patients 
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who additionally used an active rehabilitation program had a significant improvement in clinical symptoms, shortness of breath, and 
quality of life according to CAT, mMRC, and SGRQ scores, respectively. There was also a significant increase in distance during the 
6MWT in this group of patients.
Conclusions. Conducting an active rehabilitation program (physical rehabilitation in combination with an educational program 
and self-management) in group of patients with ACO and concomitant AH, who are on standard medical treatment, significantly im-
proves the bronchial response to the action of bronchodilators, decreases clinical manifestations, shortness of breath and improve quality 
of life and exercise tolerance, according to CAT, mMRC, SGRQ and 6MWT questionnaires, respectively.
Keywords: asthma-COPD overlap, arterial hypertension, functional status, quality of life, rahabilitation.
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1. Introduction 
Chronic respiratory diseases are a serious problem of modern medicine, due to their wide-
spread prevalence, high rates of mortality; also, it is a leading cause of disability and medical costs 
[1]. The most common respiratory diseases are chronic obstructive pulmonary disease (COPD) and 
asthma [2].
However, a combination of symptoms of asthma and COPD is observed in many of patients, 
especially those over 40 years of age with a history of concomitant smoking. According to various 
authors, the proportion of such patients ranges from 15 to 55 % [3]. For clinical practice, in 2014 
Global Initiative for Asthma (GINA) and Global Initiative for COPD (GOLD) guideline [4] suggest-
ed the syndrome approach and the term asthma-COPD overlap syndrome (ACOS), later changed to 
Asthma-COPD Overlap (ACO) in GINA 2017 Recommendations [3].
Most commonly, chronic respiratory disease is associated with cardiovascular disease, such 
as arterial hypertension (AH). According to the literature, the incidence of combination of AH with 
chronic respiratory disease ranges from 4 to 27 % [5].
ACO patients have significant respiratory symptoms, poor quality of life, frequent exacer-
bations that lead to more frequent medical visits, comorbidities, and increasing doses of medication 
compared to asthma and COPD [6, 7]. Studies have shown that patients with ACO have poorer 
health-related quality of life than patients with asthma or COPD alone [8].
Some studies have shown that patients with ACO have functional limitations based on such 
functional tests as the 6-minute walk test (6MWT) and BODE index, which in turn have an import-
ant prognostic relationship with mortality and exacerbation rates [9].
However, these studies excluded patients with comorbid conditions, so the impact of con-
comitant cardiac diseases on the quality of life and functional status of patients with ACO remains 
poorly understood.
Aim of the research – to investigate dynamics of functional condition and quality of life in 
with ACO and concomitant AH against the background of complex therapy.
2. Materials and methods 
The study was performed on the basis of the pulmonology department of the Municipal 
Non-commercial Enterprise «City Clinical Hospital No. 13» of Kharkiv City Council (Kharkiv, 
Ukraine) during 2018–2019. We selected for participating in the study 100 patients (48 men and 
52 women) with ACO and concomitant AH.
Inclusion criteria for the study: age 45–65 years (54.38±4.57 years; the presence of ACO 
according to the criteria recommended by the joint GINA and GOLD document on diagnosis of 
bronchial obstructive diseases from 2017 [3], the criteria of the American Thorax Society (ATS) 
[10] and the criteria of the Spanish recommendations for bronchopulmonary diseases [11].
The diagnosis was based on the presence of all 3 major criteria and at least 1 minor cri-
terion. The major criteria included: permanent airflow obstruction, age of the patient ≥40 years, 
smoking>10 years or the equivalent of air pollution, as well as documented history of asthma up to 
40 years or bronchial obstruction reversibility (BOR)>400 ml; minor criteria: a documented histo-
ry of atopy or allergic rhinitis, 2 separate BOR tests >12 % or 200 ml, and a blood eosinophil count 
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of  ≥300/μl. We selected 2 degree by GOLD (50–80 %) of airflow obstruction. Patients with stage II 
controlled AH were included in the study, whose diagnosis was determined according to the com-
monly accepted classification of blood pressure (BP) levels (as recommended by ESH/ESC) [12].
Exclusion criteria were obesity, diabetes mellitus, chronic infectious, systemic, oncological 
and psychiatric diseases, chronic heart failure with a left ventricular ejection fraction of less than 
55 %, the presence of a history of myocardial infarction, stroke and signs of ischemic heart disease, 
heart valve regurgitation more than 2 degree.
Examination of the patients included: clinical methods – analysis of complaints and medical 
history of patients, standard clinical examination with measurement of BP and heart rate (HR), 
anthropometric study with determination of body mass index (BMI), spirometry with BOR with 
inhalation of 400 mcg of salbutamol using the computer system “SPIROLAB” (manufactured by 
KhAI-Medika Research Institute in Kharkiv) according to the recommendations of ATS/ERS 
[13]. Shortness of breath was assessed by the Modified Medical Research Council Dyspnoea Scale 
(mMRS) [14], a comprehensive assessment of the severity of clinical symptoms was performed 
with COPD Assessment Test (CAT) [15], to assess the quality of life was used the questionnaire 
St. George’s Respiratory Questionnaire (SGRQ) [16]. Functional status analysis included perform-
ing the 6MWT according to ATS recommendations [17].
The study was conducted in accordance with the requirements of the GCP, the Council of 
Europe Convention on Human Rights and Biomedicine, the Helsinki Declaration of the World 
Medical Association and was approved by a local ethics committee of Kharkov Medical Academy 
of Postgraduate Education (protocol No. 5, from 12 Nov 2019). All patients signed informed con-
sent for participating in the clinical trial.
Patients were randomly divided into 2 groups of 50 patients who did not differ signifi-
cantly in age, gender, smoking status, and BMI. All patients received triple therapy in stable dos-
age: inhaled corticosteroid, prolonged β2 agonist and prolonged anticholinergic drug according to 
GINA / GOLD recommendations [3]. In addition to basic therapy, patients in the first group were 
provided with a rehabilitation program, recommended by GOLD, which included: an education-
al program (smoking cessation, correct use of inhaler devices, early recognition of exacerbation, 
decision-making and taking action, and when to seek help), the formation of self-management 
skills (goals of motivating, engaging and supporting the patients to positively adapt their health 
behavior(s) and develop skills to better manage their disease), a program of complex physical reha-
bilitation (strength training and aerobic training, upper extremities exercise training, inspiratory 
muscle training and metered walking) [18]. At the baseline all patients were assessed for spirometry 
with BOR test, BP and HR measurment, exercise tolerance by using 6MWT. This program was 
monitored on a weekly visit. The re-evaluation was performed after 16 weeks of comprehensive 
treatment. The examination was carried out during a period of remission characterized by stable 
clinical symptoms and indicators of respiratory function.
The obtained data were processed using the Statistic application. Quantitative data are pre-
sented as mean values (M) and standard deviations (SD). To describe qualitative variation, we used 
the frequency at which the traits were assessed in the group. The critical significance level of statis-
tical significance at the null hypothesis test was assumed to be 0.05. Parametric and non-parametric 
methods were used to compare the central parameters of the groups: Student’s t-test, Wilcoxon 
tests (W) and Mann-Whitney (MU). The pairwise comparison of groups used the criterion U –
Mann-Whitney (MU), to compare the occurrence of a feature in the frequency analysis in groups 
used the Pearson test χ-square (χ2).
3. Results
The initial clinical and functional characteristics of the patients are presented in Table 1. 
The average age of the examined patients was 54.38±4.57 years. Patients had extensive smoking 
experience (29.82±6.22 packs) and were active smokers (70 patients) or smokers in the past (30 pa- 
tients). All examined patients had a normal body weight (BMI of 25.15±2.12 kg/m2). Patients in 
both groups did not differ significantly in sex, smoking status, BP, HR, and BMI.
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Clinical and functional characteristics of patients
Indicators
ACO with AH, n=100
Group 1 Group 2
Р>0,05
n=50 n=50
Age, years 53.62±4.18 55.14±5.01 0.103
Gender, women/men 26(52 %)/24 (48 %) 25(50 %)/25 (50 %) 0.842
Smoking status, smokers/smokers in the past 34 (68 %)/16 (32 %) 36 (72 %)/14 (28 %) 0.663
Smoking experience, pack/years 30.42±6.08 28.86±4.98 0.163
BMI, kg/m2 25.92±7.19 24.42±8.08 0.329
Systolic BP, mm Hg 136.16±9.15 134.84±10.12 0.496
Diastolic BP, mm Hg 82.43±8.48 85.36±10.95 0.138
HR, beat/min 73.22±9.73 75.46±7.57 0.202
There was also no discrepancy between the baseline condition of patients in both groups in 
spirometry results and quality of life.
A re-evaluation of spirometry after 16 weeks of treatment there were no changes in lung 
functional status in patients on standard treatment (group 2). At the same time, in the context of 
complex treatment in patients who had an active rehabilitation program (group 1), there was a sig-
nificant improvement in the bronchial response to the action of bronchodilators (p=0.033), although 
other indicators of the functional status of the lungs did not show significant changes (Tables 2, 3).
Table 2






FEV 1, % of predicted 64.12±13.82 68.38±14.83 0.140
FEV 1/ FVC, % 64.27±5.68 66.21±6.94 0.129
FEF 25, % of predicted 25.16±16.91 27.35±17.46 0.526
FEF 50, % of predicted 23.91±9.67 28.57±8.83 0.014
FEF 75, % of predicted 28.92±12.82 30.26 ±14.42 0.625
FVC, % of predicted 77.45±14.94 81.46±16.29 0.203
Reversibility after bronchodilator inhalation, % 18.05±5.63 20.12 ± 3.78 0.033
CAT, points 18.86±7.26 15.36±6.38 0.012
mMRС, points 2.23±0.62 1.84±0.86 0.018
SGRC, points 43.86±17.24 34.56±16.87 0.010
6MWT, meters 435.61±78.63 476.45±66.56 0.010
The quality of life scores varied significantly between groups. There were no significant 
changes in quality of life in standard-treated patients (Table 3). At the same time, patients who addi-
tionally used an active rehabilitation program had a significant improvement in clinical symptoms, 
shortness of breath, and quality of life according to CAT, mMRC, and SGRQ scores, respectively 
(Table 2). There was also a significant increase in distance during the 6MWT in Group 1.
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FEV 1, % of predicted 63.96±12.62 64.21±14.55 0.927
FEV 1/ FVC, % 63.72±5.48 62.87±6.28 0.473
FEF 25, % of predicted 25.51±9.94 25.82±8.86 0.870
FEF 50, % of predicted 24.56±6.34 24.94±7.45 0.784
FEF 75, % of predicted 28.76±11.22 29.02±13.81 0.918
FVC, % of predicted 77.03±16.97 75.84±15.27 0.622
Reversibility after bronchodilator inhalation, % 17.56±6.23 17.64±5.27 0.945
CAT, points 19.06±8.04 18.89±7.25 0.912
mMRС, points 2.18±0.58 2.06±0.72 0.361
SGRC, points 40.68±14.83 39.74±11.28 0.722
6MWT, meters 427.87±68.45 435.84±70.26 0.567
4. Discussion
Patients with ACO have severe manifestations. The use of all medicines included in the 
standard of treatment of these group patients, unfortunately, have limited potential to influence the 
organic changes in the lungs, which determine the functional parameters of spirometry. 
AH may have an additional negative effect on functional status and quality of life on 
this group of patients. The B. Ding and M. Small study showed a significantly higher rate of 
concomitant cardiac comorbidity, including AH in COPD and ACO patients, compared to 
asthma alone [19], the same results were obtained by DJ Maselli et al [20], but these studies 
did not investigate the influence of concomitant AH on the course of ACO regarding quality 
of life, functional status.
A number of studies have found significantly higher levels of symptoms and exacerbations, 
decreased quality of life [8, 20] and functional status of patients with ACO [9, 21, 22], however, 
studies have not analyzed the association of complaints, clinical, and functional status with con-
comitant pathology of patients.
Some studies have aimed to find ways that can improve the quality of life and functionality 
in patients with ACO on the background of basic drug therapy. A. Rodrigues et al, when investigat-
ing the effectiveness of a 12-week training program in patients with ACO compared patients with 
COPD, received improvements in pulmonary function, 6MWT, peripheral and inspiratory muscle 
strength, SGRQ, however, no significant difference was found in the results of the two groups, as 
well as differences in 6MWT and mMRC in the dynamics of treatment [23, 24]. The fatigue of 
our study showed that conducting an active rehabilitation program (physical rehabilitation in com-
bination with an educational program) in patients with ACO with concomitant AH significantly 
improves the bronchial response to the action of bronchodilators by spirometry test, reduces the 
clinical manifestation and exercise tolerance, according to CAT, mMRC, SGRQ, and 6MWT ques-
tionnaires, respectively.
The limitations of the research. The present study was intended to investigate only the 
functional status and quality of life ACO patients with concomitant AH and did not include anal-
ysis of clinical and laboratory parameters for these patient groups, as well as the study of patients 
with other chronic respiratory diseases and variants of comorbidity.
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The further research plan includes the study of clinical and laboratory status in patients 
with ACO with concomitant AH, analysis BP, HR, saturation rates in dynamics of complex therapy 
in ACO with AH group of patients.
5. Conclusions 
Conducting an active rehabilitation program (physical rehabilitation in combination with an 
educational program and self-management) in group of patients with ACO and concomitant AH, 
who are on standard medical treatment, significantly improves the bronchial response to the action 
of bronchodilators, decreases clinical manifestations, shortness of breath and improve quality of life 
and exercise tolerance, according to CAT, mMRC, SGRQ and 6MWT questionnaires, respectively.
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Abstract
Diabetes mellitus is one of the most serious problems of the clinical medicine. This is determined by the fact that it is followed 
by multisystemic affects, as well as complications on the side of other organs and systems, among which a special place is occupied by 
gastroesophageal reflux disease. As for the combination and mutual influence of diabetes mellitus and gastroesophageal reflux disease, 
this issue has not been studied yet, the data of modern literature are not complete and quite contradictory. 
The aim of the study: to investigate the state of the factors of aggression and protection of the oesophageal mucosa in patients 
with diabetes mellitus type II with concomitant gastroesophageal reflux disease without associated pathology. 
Method. There were two groups of patients under observation. The first group included 45 patients with diabetes mellitus type 
II with concomitant gastroesophageal reflux disease (26 men and 19 women). The second group included 38 patients with gastroesoph-
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